These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 21317650)
21. Validation of the PELOD score for multiple organ dysfunction in children. Thukral A; Kohli U; Lodha R; Kabra SK; Kabra NK Indian Pediatr; 2007 Sep; 44(9):683-6. PubMed ID: 17921557 [TBL] [Abstract][Full Text] [Related]
22. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database. de Pont AC; Bakx R; Boermeester MA; Schultz MJ Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262 [No Abstract] [Full Text] [Related]
23. Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. Matics TJ; Sanchez-Pinto LN JAMA Pediatr; 2017 Oct; 171(10):e172352. PubMed ID: 28783810 [TBL] [Abstract][Full Text] [Related]
24. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results. Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514 [TBL] [Abstract][Full Text] [Related]
25. Role of activated protein C in the pathophysiology of severe sepsis. Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357 [TBL] [Abstract][Full Text] [Related]
26. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Micek ST; Isakow W; Shannon W; Kollef MH Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217 [TBL] [Abstract][Full Text] [Related]
27. A prospective, observational study of Xigris Use in the United States (XEUS). Steingrub JS; Cheatham ML; Woodward B; Wang HT; Effron MB; J Crit Care; 2010 Dec; 25(4):660.e9-16. PubMed ID: 20435433 [TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013 [TBL] [Abstract][Full Text] [Related]
29. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562 [TBL] [Abstract][Full Text] [Related]
30. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Martí-Carvajal AJ; Solà I; Gluud C; Lathyris D; Cardona AF Cochrane Database Syst Rev; 2012 Dec; 12(12):CD004388. PubMed ID: 23235609 [TBL] [Abstract][Full Text] [Related]
31. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632 [TBL] [Abstract][Full Text] [Related]
32. Use of drotrecogin alfa (activated) in older patients with severe sepsis. Alexander SL; Ernst FR Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513 [TBL] [Abstract][Full Text] [Related]
33. A multicenter evaluation of the safety of drotrecogin alfa (activated) in patients with baseline bleeding precautions. Benefield RJ; Drevets DA; Huycke MM; Gentry CA Curr Drug Saf; 2012 Feb; 7(1):3-7. PubMed ID: 22663949 [TBL] [Abstract][Full Text] [Related]
34. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR; Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631 [TBL] [Abstract][Full Text] [Related]
35. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy. Degoricija V; Sharma M; Legac A; Gradiser M; Sefer S; Vucicević Z Croat Med J; 2006 Jun; 47(3):385-97. PubMed ID: 16758516 [TBL] [Abstract][Full Text] [Related]
36. Drotrecogin alfa (activated) in severe sepsis. Friedrich JO N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311 [No Abstract] [Full Text] [Related]
37. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis. Barie PS; Hydo LJ; Shou J; Eachempati SR Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513 [TBL] [Abstract][Full Text] [Related]
38. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381 [TBL] [Abstract][Full Text] [Related]
39. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis. McCoy C Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421 [TBL] [Abstract][Full Text] [Related]
40. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH. Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]